Recombinant Human GRO-γ/CXCL3

Description :
FAQ COA 已发表文献 Human GRO alpha, GRO beta (MIP-2 alpha ), and GRO gamma (MIP-2 beta ) are products of three distinct, non-allelic human genes. GRO beta and GRO gamma share 90% and 86% amino acid sequence homology, respectively, with GRO alpha. All three human GROs are members of the alpha (C-X-C) subfamily of chemokines and are thought to be the homologs ofmurine KC and MIP-2. The three GRO cDNAs encode 107 amino acid precursor proteins from which the N-terminal 34 amino acid residues are cleaved to generate the mature GROs. There are no potential N-linked glycosylation sites in the amino acid sequences. GRO expression is inducible by serum or PDGF and/or by a variety of inflammatory mediators, such as IL-1 and TNF, in monocytes, fibroblasts, melanocytes and epithelial cells. In certain tumor cell lines, GRO is expressed constitutively. Similar to other alpha chemokines, the three GRO proteins are potent neutrophil attractants and activators. In addition, these chemokines are also active toward basophils. All three GROs can bind with high affinity to the IL-8 receptor type B. Product Properties Synonyms GRO-gamma, MIP2-beta Accession P19876 GeneID 2921 Source E.coli-derived Human GRO-,Ala35-Asn107. Molecular Weight Approximately 7.9 kDa AA Sequence ASVVTELRCQ CLQTLQGIHL KNIQSVNVRS PGPHCAQTEV IATLKNGKKA CLNPASPMVQ KIIEKILNKG STN Tag None Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder. Purity > 97% by SDS-PAGE and HPLC analyses. Biological Activity Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human CXCR2 transfected human 293 cells is in a concentration range of 10-100 ng/mL. Endotoxin Formulation Lyophilized from a 0.2 m filtered concentrated solution in 20 mM PB, pH 7.4, 50 mM NaCl. Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at -20C. Further dilutions should be made in appropriate buffered solutions.